-transparent.png){kind=logo}
The use of an antitachycardia pacemaker in the treatment of hyperkinetic supraventricular arrhythmias is founded on a reliable electrophysiological ground and on an high technology. Nevertheless the clinical impact of this approach is not considerable since the 5% to 7% of the potential candidates are in effect treated with an antitachycardia device. The success of new therapeutical procedures (i.e. catheter ablation) together with the shifting of the clinical, technical and commercial interest towards the electrical treatment of the malignant ventricular tachyarrhythmias are the main causes of the minor role that now the antitachycardia pacemakers play in the management of the patients with hyperkinetic supraventricular arrhythmias.
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1980,
Revista espanola de cardiologia,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
September 1986,
Cardiologia (Rome, Italy),
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1983,
Giornale italiano di cardiologia,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1981,
Giornale italiano di cardiologia,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1987,
Health technology,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
September 1982,
Minerva cardioangiologica,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1981,
Bollettino della Societa italiana di cardiologia,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
February 1987,
Fortschritte der Medizin,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1974,
Bollettino della Societa italiana di cardiologia,
G Vergara, and
G Inama, and
M Guarnerio, and
L Gramegna, and
F Furlanello
January 1990,
Revista espanola de cardiologia,
